Altimmune develops pemvidutide, an investigational peptide treatment for serious liver diseases such as MASH. It last closed at $1.53 on Nov 17, down 1.92% on the day. The average 12-month price target from 2 analysts is $12.50 (+717.0% from the last close), with a high of $14.00 and a low of $11.00.
Only 2 firms rated ALT in the past 90 days, not enough for a consensus
Average 12-month target
$12.50
▲ 717.0% upside
Based on 2 analysts who set a price target on ALT in the past 90 days. The average target is $12.50, with a high of $14.00 and a low of $11.00, compared with the last close of $1.53.
Highest target$14.00
Average target$12.50
Lowest target$11.00
Latest rating changes
Evercore ISI GroupTarget lowered
Nov 16Buy$17 → $14
B. Riley SecuritiesReiterated
Nov 13Buy$11
Evercore ISI GroupMaintained
Sep 23Buy$17
Leerink PartnersInitiated
Jun 22Buy$10
HC Wainwright & Co.Maintained
May 18Buy$20
Date
Firm
Action
Rating
Price target
Nov 16
Evercore ISI Group
Target lowered
Buy
$17 → $14
Nov 13
B. Riley Securities
Reiterated
Buy
$11
Sep 23
Evercore ISI Group
Maintained
Buy
$17
Jun 22
Leerink Partners
Initiated
Buy
$10
May 18
HC Wainwright & Co.
Maintained
Buy
$20
Loading…
Technical Analysis
ALT · as of the Nov 17 close · updated after every close
Downtrend, oversold
The stock is 29% below its 20 day and 64% below its 50 day average. It is 102% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 24), oversold. The nearest support is the Pivot S1 at $1.51, and the nearest resistance the Pivot R1 at $1.55.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 8.9%/day
Key levels
$6.4452 week high+320.9%
$3.09200 day average+102.0%
$2.77100 day average+81.0%
$2.5150 day average+64.1%
$2.18Swing high (Oct 29)+42.5%
$1.9720 day average+28.8%
$1.55Pivot R1+1.3%
$1.53Pivot+0.0%
$1.53Last close
$1.51Pivot S1−1.3%
$1.5052 week low−2.0%
Indicators
RSI (14)
23.93
Oversold below 30
Oversold
MACD
-0.24
Below its signal line
Bearish
Stochastic
7.4
Near the bottom of its range
Oversold
ADX (14)
43.2
Strong downtrend
Williams %R
-95.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-196.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−25.0%
Change over 10 sessions
Bearish
ATR (14)
$0.14
Typical daily range, 8.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling, oversold
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchOversold
VolatilityNormal, 23.8%/day
Key levels
$6.4452 week high+320.9%
$3.09200 day average+102.0%
$2.77100 day average+81.0%
$2.5150 day average+64.1%
$2.18Swing high (Oct 29)+42.5%
$1.9720 day average+28.8%
$1.55Pivot R1+1.3%
$1.53Pivot+0.0%
$1.53Last close
$1.51Pivot S1−1.3%
$1.5052 week low−2.0%
Indicators
RSI (14)
26.64
Oversold below 30
Oversold
MACD
-0.40
Below its signal line
Bearish
Stochastic
5.0
Near the bottom of its range
Oversold
ADX (14)
18.6
No clear trend
Williams %R
-98.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-173.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−53.2%
Change over 10 sessions
Bearish
ATR (14)
$0.36
Typical daily range, 23.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for ALT
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how ALT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow ALT usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ALT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALT is in one of them and how their past ALT trades turned out.
Altimmune is a biopharmaceutical company based in Gaithersburg, Maryland, that develops treatments for serious liver diseases. Its lead product candidate, pemvidutide, is an investigational peptide designed to act on both glucagon and GLP-1 receptors. The company is studying pemvidutide for steatohepatitis, a form of fatty liver disease, as well as for alcohol use disorder and liver disease caused by alcohol. Its target patients are people living with these conditions, and the drug is not yet approved for sale.